Furthermore, five therapeutic target genes (HMMR, CCNB1, CDC25C, AURKA, and CENPE) and five drugs (oligomycin A, panobinostat, (+)-JQ1, voxtalisib, and arcyriaflavin A) were identified for those high-risk breast cancer patients, with the potential to improve current population-based therapeutic strategies in breast cancer management. This evidence concerns the gene CDC25C and breast carcinoma.